IN2014MN01907A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01907A IN2014MN01907A IN1907MUN2014A IN2014MN01907A IN 2014MN01907 A IN2014MN01907 A IN 2014MN01907A IN 1907MUN2014 A IN1907MUN2014 A IN 1907MUN2014A IN 2014MN01907 A IN2014MN01907 A IN 2014MN01907A
- Authority
- IN
- India
- Prior art keywords
- composition
- festinavir
- nevirapine
- lamivudine
- retroviruses
- Prior art date
Links
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 230000000798 anti-retroviral effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- OSYWBJSVKUFFSU-SKDRFNHKSA-N festinavir Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@](CO)(C#C)O1 OSYWBJSVKUFFSU-SKDRFNHKSA-N 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract 1
- 229960001627 lamivudine Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960000689 nevirapine Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1907MUN2014 IN2014MN01907A (enExample) | 2012-03-05 | 2013-03-05 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN583MU2012 | 2012-03-05 | ||
| PCT/GB2013/000092 WO2013132208A1 (en) | 2012-03-05 | 2013-03-05 | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine |
| IN1907MUN2014 IN2014MN01907A (enExample) | 2012-03-05 | 2013-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01907A true IN2014MN01907A (enExample) | 2015-07-10 |
Family
ID=47884388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1907MUN2014 IN2014MN01907A (enExample) | 2012-03-05 | 2013-03-05 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150104511A1 (enExample) |
| EP (1) | EP2822560A1 (enExample) |
| JP (1) | JP2015509524A (enExample) |
| KR (1) | KR20140138837A (enExample) |
| CN (1) | CN104203244A (enExample) |
| AU (1) | AU2013229274A1 (enExample) |
| BR (1) | BR112014021927A2 (enExample) |
| CA (1) | CA2866133A1 (enExample) |
| IN (1) | IN2014MN01907A (enExample) |
| MX (1) | MX2014010337A (enExample) |
| RU (1) | RU2014140177A (enExample) |
| WO (1) | WO2013132208A1 (enExample) |
| ZA (1) | ZA201406495B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2898092A1 (en) * | 2013-02-07 | 2014-08-14 | Tobira Therapeutics, Inc. | Lamivudine salts |
| EP3153157A1 (en) | 2015-10-09 | 2017-04-12 | Teva Pharmaceutical Works Private Limited Company | Pharmaceutical composition for prolonged release of nevirapine |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TW202024061A (zh) | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| ES2958828T3 (es) | 2018-02-15 | 2024-02-15 | Gilead Sciences Inc | Derivados de piridina y su uso para tratar una infección por VIH |
| CN120078775A (zh) | 2018-07-16 | 2025-06-03 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| JP7503558B2 (ja) | 2019-01-25 | 2024-06-20 | ブラウン ユニバーシティ | 加齢関連炎症および障害を治療する、予防するまたは逆転させるための組成物および方法 |
| JP7520162B2 (ja) | 2020-06-25 | 2024-07-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖの治療のためのカプシド阻害剤 |
| PE20241341A1 (es) | 2021-12-03 | 2024-07-03 | Gilead Sciences Inc | Compuestos terapeuticos para la infeccion por el virus vih |
| TW202342447A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於ｈｉｖ病毒感染之治療性化合物 |
| US12084467B2 (en) | 2021-12-03 | 2024-09-10 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2083668T5 (es) | 1991-05-16 | 2001-06-16 | Glaxo Group Ltd | Combinaciones antiviricas que contienen analogos de nucleosido. |
| GB9622681D0 (en) | 1996-10-31 | 1997-01-08 | Glaxo Group Ltd | Pharmaceutical compositions |
| PT1035834E (pt) * | 1997-12-05 | 2002-09-30 | Alza Corp | Forma de dosagem osmotica que compreende primeiro e segundo revestimentos |
| EA003327B1 (ru) | 1998-01-16 | 2003-04-24 | Медивир Аб | Антивирусные соединения |
| GB9809213D0 (en) | 1998-04-29 | 1998-07-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| WO2004087169A1 (en) | 2003-03-27 | 2004-10-14 | Boehringer Ingelheim International Gmbh | Antiviral combination of nevirapine and a further antiretroviral compound |
| WO2007026156A1 (en) * | 2005-08-31 | 2007-03-08 | Cipla Limited | Pharmaceutical combinations containing lamivudine, stavudine and nevirapine |
| DK2155169T3 (en) * | 2007-06-08 | 2016-06-13 | Boehringer Ingelheim Int | Formulation of nevirapine extended release |
-
2013
- 2013-03-05 KR KR20147027819A patent/KR20140138837A/ko not_active Withdrawn
- 2013-03-05 CN CN201380012366.4A patent/CN104203244A/zh active Pending
- 2013-03-05 US US14/382,444 patent/US20150104511A1/en not_active Abandoned
- 2013-03-05 CA CA2866133A patent/CA2866133A1/en not_active Abandoned
- 2013-03-05 JP JP2014560438A patent/JP2015509524A/ja active Pending
- 2013-03-05 AU AU2013229274A patent/AU2013229274A1/en not_active Abandoned
- 2013-03-05 EP EP13709491.8A patent/EP2822560A1/en not_active Withdrawn
- 2013-03-05 MX MX2014010337A patent/MX2014010337A/es unknown
- 2013-03-05 BR BR112014021927A patent/BR112014021927A2/pt not_active IP Right Cessation
- 2013-03-05 WO PCT/GB2013/000092 patent/WO2013132208A1/en not_active Ceased
- 2013-03-05 IN IN1907MUN2014 patent/IN2014MN01907A/en unknown
- 2013-03-05 RU RU2014140177A patent/RU2014140177A/ru not_active Application Discontinuation
-
2014
- 2014-09-04 ZA ZA2014/06495A patent/ZA201406495B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140138837A (ko) | 2014-12-04 |
| EP2822560A1 (en) | 2015-01-14 |
| WO2013132208A8 (en) | 2013-11-07 |
| CN104203244A (zh) | 2014-12-10 |
| AU2013229274A1 (en) | 2014-09-04 |
| MX2014010337A (es) | 2014-11-14 |
| ZA201406495B (en) | 2016-03-30 |
| RU2014140177A (ru) | 2016-04-27 |
| US20150104511A1 (en) | 2015-04-16 |
| BR112014021927A2 (pt) | 2019-09-24 |
| WO2013132208A1 (en) | 2013-09-12 |
| CA2866133A1 (en) | 2013-09-12 |
| JP2015509524A (ja) | 2015-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01907A (enExample) | ||
| IN2013MU01749A (enExample) | ||
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| PH12014501738A1 (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| PH12015501156A1 (en) | Pharmaceutical compositions | |
| TN2015000185A1 (en) | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group | |
| UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
| PH12016501968A1 (en) | Novel macrocyclic compounds | |
| CY1119957T1 (el) | Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος | |
| CY1118074T1 (el) | Ανθελονοσιακοι παραγοντες | |
| EA201790495A1 (ru) | Фармацевтические композиции длительного действия | |
| EP4424373A3 (en) | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine | |
| MX2016000037A (es) | Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
| PH12015502746A1 (en) | Prodrug derivatives of substituted triazolopyridines | |
| PH12015500322B1 (en) | Tris(hetero)arylpyrazoles and use thereof | |
| CY1118913T1 (el) | Νεοι ανθελονοσιακοι παραγοντες | |
| BR112017003252A2 (pt) | terapia com anticorpos contra hiv como substituto de tratamento | |
| IN2013CH05288A (enExample) | ||
| JO3641B1 (ar) | تركيبة مضادات الفيروسات القهقرية | |
| PH12015502703A1 (en) | Pharmaceutical compositions | |
| CY1116711T1 (el) | Νεοι ανθελονοσιακοι παραγοντες |